Keeping patients safe: Merck Millipore
passes first EXCiPACT™ audit
New internationally accepted certification scheme for pharmaceutical excipient suppliers
Merck Millipore has now become one of the first companies to successfully complete a comprehensive EXCiPACT™ audit. Following this positive assessment, Merck Millipore will undergo recertification audits every three years, plus annual surveillance audits to ensure the continued safety and quality of excipients.
What is EXCiPACT™?
Until recently, there were no certifiable GMP and GDP (Good Manufacturing Practice, Good Distribution Practice) standards for the pharmaceutical excipients that make up the bulk of most drug formulations. So the pharmaceutical excipients industry launched EXCiPACT™ – a new certification scheme for pharmaceutical excipients that grants an independent, one-stop ‘seal of approval’ by third-party auditors. With EXCiPACT™, a single audit will be all it takes to prove an excipient complies with current GMP and GDP requirements. This certification for manufacturers, suppliers and distributors of pharmaceutical excipients minimizes risks to customers and helps ensure patient safety while reducing costs.
EXCiPACT™ is the result of a voluntary initiative of the pharmaceutical excipients industry to ensure excipient quality throughout the entire supply chain by self-regulation. Industry experts from EFCG, IPEC Europe, IPEC Americas, FECC, and PQG are involved in its development.
|The benefits to you|
To learn more about EXCiPACT™ please visit www.excipact.org.